Sugi Predict

Sugi Predict / Compounds / SCHEMBL2844839

SCHEMBL2844839

SCHEMBL2844839

NS(=O)(=O)c1cc2cc(P(=O)(O)O)c(=O)[nH]c2cc1Cl

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 10/20 0.40
▸ CA1 P00915 10/20 0.40
▸ CA2 P00918 10/20 0.40
▸ CA9 Q16790 10/20 0.40
▸ CA3 P07451 7/20 0.40
▸ CA4 P22748 7/20 0.40
▸ CA6 P23280 7/20 0.40
▸ CA5A P35218 7/20 0.40
▸ CA7 P43166 7/20 0.40
▸ CA14 Q9ULX7 7/20 0.40
▸ CA5B Q9Y2D0 7/20 0.40
▸ CA13 Q8N1Q1 6/20 0.40
▸ CISD1 Q9NZ45 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ GRIN2D O15399 1/20 0.35
▸ GRIN3B O60391 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7648730 0.84 GRIN2D (0.35) KDM4EMEN1GRIN2DGRIN3BALDH1A1
SCHEMBL6927156 0.84 DAO (0.33) CA12CA1CA2CA9GRIN2D
SCHEMBL7652253 0.83 ALDH1A1 (0.40) KDM4EGRIN2DGRIN3BALDH1A1LMNA
SCHEMBL6939746 0.83 GRIN2D (0.37) KDM4EMEN1GRIN2DGRIN3BALDH1A1
SCHEMBL974565 0.82 GRIN2D (0.48) KDM4EMEN1GRIN2DGRIN3BALDH1A1
SCHEMBL6927437 0.81 CA1 (0.41) CA12CA1CA2CA9CA4
SCHEMBL6926873 0.80 USP2 (0.38) CA12CA1CA2CA9CA3
SCHEMBL7648786 0.80 GRIN1 (0.35) KDM4EGRIN2DGRIN3BALDH1A1LMNA
SCHEMBL7652655 0.80 GSTO1 (0.37) KDM4EGRIN2DGRIN3BALDH1A1GRIA1
SCHEMBL7652701 0.80 KDM4E (0.37) KDM4EGRIN2DGRIN3BALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140162964-A1 USE IN BRAIN DEGENERATIVE DISEASES NOVARTIS AG (CH) 2014-06-12 — — US claimed
EP-2213285-B1 Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases NOVARTIS AG (CH) 2013-11-06 — — EP claimed
US-6596709-B1 For treatment of Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Huntington's chorea LES LABORATOIRES SERVIER (FR) 2003-07-22 — — US claimed
EP-1125941-B1 Derivatives of 6-sulfamoyl-3-quinolyl phosphonic acids, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-04-09 — — EP claimed
US-6518258-B1 6-sulphamoyl -3-quinolyphosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2003-02-11 — — US claimed
EP-2468732-B1 1H-Quinazoline-2,4-diones NOVARTIS AG (CH) 2014-08-20 — — EP disclosed
US-20140162964-A1 USE IN BRAIN DEGENERATIVE DISEASES NOVARTIS AG (CH) 2014-06-12 — — US disclosed
US-20130296332-A1 1H-QUINAZOLINE-2,4-DIONES NOVARTIS AG (CH) 2013-11-07 — — US disclosed
EP-2213285-B1 Use of sphingosine-1-phosphate (S1P) receptor agonists in combination with a second agent for the treatment of brain degenerative diseases NOVARTIS AG (CH) 2013-11-06 — — EP disclosed
US-20130281541-A1 USE IN BRAIN DEGENERATIVE DISEASES BRINKMANN VOLKER (DE) 2013-10-24 — — US disclosed
US-8519006-B2 Use of sphingosine-1 phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases NOVARTIS AG (CH) 2013-08-27 — — US disclosed
US-8513268-B2 1H-quinazoline-2,4-diones processes for their production, pharmaceutical compositions, and treatment for epilepsy NOVARTIS AG (CH) 2013-08-20 — — US disclosed
WO-2005049039-A1 COMBINATIONS COMPRISING AMPA RECEPTORS ANTAGONISTS FOR THE TREATMENT OF AFFECTIVE AND ATTENTION DEFICIT DISORDERS NOVARTIS AG (CH) 2005-06-02 — — WO disclosed
WO-2005049042-A1 COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF TINNITUS NOVARTIS AG (CH) 2005-06-02 — — WO disclosed
WO-2005049041-A1 COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ANXIETY DISORDERS NOVARTIS AG (CH) 2005-06-02 — — WO disclosed
WO-2005049040-A1 COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SCHIZOPHRENIA NOVARTIS AG (CH) 2005-06-02 — — WO disclosed
WO-2005039593-A1 COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF NEUROPATHIC PAIN NOVARTIS AG (CH) 2005-05-06 — — WO disclosed
WO-2005039594-A1 COMBINATIONS COMPRISING AMPA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MYOPIA NOVARTIS AG (CH) 2005-05-06 — — WO disclosed
US-6596709-B1 For treatment of Alzheimer's disease, schizophrenia, amyotrophic lateral sclerosis, and Huntington's chorea LES LABORATOIRES SERVIER (FR) 2003-07-22 — — US disclosed
US-6518258-B1 6-sulphamoyl -3-quinolyphosphonic acid compounds LES LABORATOIRES SERVIER (FR) 2003-02-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130281541-A1 USE IN BRAIN DEGENERATIVE DISEASES S1PR1, S1PR2, S1PR3 CA12 4679/4885CA1 4165/4885CA2 4695/4885
US-20130296332-A1 1H-QUINAZOLINE-2,4-DIONES CYP1A2, QDPR, CYP3A7 CA12 3678/4885CA1 3105/4885CA2 2383/4885
US-20140162964-A1 USE IN BRAIN DEGENERATIVE DISEASES S1PR1, S1PR2, S1PR3 CA12 4679/4885CA1 4165/4885CA2 4695/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.